Skip to main
HUM
HUM logo

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 12%
Buy 29%
Hold 59%
Sell 0%
Strong Sell 0%

Bulls say

Humana's earnings per share (EPS) estimate for 2025 has been raised to $17.06, reflecting strong second-quarter results and updated guidance, indicating positive financial momentum. The company anticipates a year-over-year increase in earnings for 2027 as margin improvement initiatives take effect, despite the assumption that bonus payments from the Star Ratings program will not recover. Additionally, Humana's above-industry Medicare Advantage star rating profile strengthens its competitive position in the face of regulatory changes, further supporting a favorable long-term outlook.

Bears say

The financial outlook for Humana appears negative, primarily due to management's expectation of a decline in earnings per share (EPS) for 2026 compared to 2025, despite efforts to offset this decrease through margin initiatives. Additionally, various downside risks, including increased competition in Medicare Advantage (MA), inadequate reimbursement rates, and declining Star ratings, could impact profitability and growth, further contributing to a potential EPS shortfall of approximately 10% in FY27. Finally, while management believes there may be a sustained benefit gap against competitors, underlying pressures from the healthcare services sector and challenges in responding to market dynamics remain concerning for the company's future performance.

Humana (HUM) has been analyzed by 17 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 29% recommend Buy, 59% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 17 analysts, Humana (HUM) has a Hold consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $299.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $299.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.